Contact Information
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
PediatricsHematology & Oncology700 Children’s DrColumbus, OH 43205 (map)
Learn more about Amy L. Dunn
Biography
Dr Dunn received her medical degree from Wright State University School of Medicine in Dayton, Ohio and completed her pediatric and pediatric hematology/oncology training at Emory University in Atlanta, Georgia. She is an Associate Professor of Pediatrics at Nationwide Children's Hospital/Ohio State University where she is the Director of Pediatric Hematology and directs the Hemophilia Treatment Center.
She is a member of various professional associations including the American Society of Hematology, World Federation of Hemophilia, The International Society of Thrombosis and Hemostasis, the International Pediatric Hemophilia Network, the International Prophylaxis Study Group and the Hemophilia and Thrombosis Research Society (HTRS). Dr Dunn has served as a reviewer for hematologic journals including the Journal of Pediatric Blood and Cancer, the Journal of Thrombosis and Hemostasis, Blood and Haemophilia. She has published numerous peer-reviewed articles, abstracts, and textbook chapters. In addition, she has given many presentations at national and international medical conferences and has received awards that include US News and World Report Top Doctors and the Atlanta Business Chronicle Healthcare Hero for Healthcare Innovation.
Patient Care
Locations
Westerville Sports Medicine and Orthopedic Center
Main Campus of Nationwide Children’s Hospital
Academic and Clinical Areas
Hemostasis and Thrombosis Center
Director
Hematology/Oncology & BMT
Director
Hematology, Oncology and BMT Fellowship
Faculty
Pediatric Hemostasis-Thrombosis Fellowship
Faculty
Primary Department
Pediatrics
Primary Section
Hematology & Oncology
Awards, Honors & Organizations
Listed, Best Doctors in America
Research
Publications
Pierce GF, Adediran M, Diop S, Dunn AL, El Ekiaby M, Kaczmarek R, Konkle BA, Pipe SW, Skinner MW, Valentino LA, Robinson F, Ampartzidis G, Martin J, Haffar A. Achieving access to haemophilia care in low-income and lower-middle-income countries: expanded Humanitarian Aid Program of the World Federation of Hemophilia after 5 years. Lancet Haematol. 2022 Sep; 9: e689-e697.
Kumar R, Dunn A, Schneiderman JE, Gonzales A, Bouskill V, Widener P, Stanek J, Pluthero FG, Waller A, Tarango C, Ahuja S, Kerlin BA, Kahr WH, Rand ML, Lillicrap D, Carcao M. Moderate-intensity aerobic exercise versus desmopressin in adolescent males with mild hemophilia A: a randomized trial. Blood. 2022 Jul 15;
Escobar M, Dunn A, Quon D, Trzaskoma B, Lee L, Ko RH, Carpenter SL. A phase IV, multicentre, open-label study of emicizumab prophylaxis in people with haemophilia A with or without FVIII inhibitors undergoing minor surgical procedures. Haemophilia. 2022 May 5;
Pipe SW, Hermans C, Chitlur M, Carcao M, Castaman G, Davis JA, Ducore J, Dunn AL, Escobar M, Journeycake J, Khan O, Mahlangu J, Meeks SL, Mitha IH, Négrier C, Nowak-Göttl U, Recht M, Chrisentery-Singleton T, Stasyshyn O, Vilchevska KV, Martinez LV, Wang M, Windyga J, Young G, Alexander WA, Bonzo D, Macie C, Mitchell IS, Sauty E, Wilkinson TA, Shapiro AD. Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors. Haemophilia. 2022 Apr 27;
Königs C, Ozelo MC, Dunn A, Kulkarni R, Nolan B, Brown SA, Schiavulli M, Gunawardena S, Mukhopadhyay S, Jayawardene D, Winding B, Carcao M. First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results. Blood. 2022 Apr 12;
Rodriguez V, Stanek J, Kerlin BA, Dunn AL. Andexanet Alfa Versus Prothrombin Complex Concentrates/Blood Products as Apixaban/Rivaroxaban Reversal Agents: A Survey Among Pediatric Hematologists. Clin Appl Thromb Hemost. 2022 Jan-Dec; 28: 10760296221078842.
Wysocki EL, Kuhn A, Steinbrenner J, Tyrrell L, Abdel-Rasoul M, Dunn A, Cloyd C. Enoxaparin Dose Requirements to Achieve Therapeutic Low-molecular-weight Heparin Anti-factor Xa Levels in Infants and Young Children. J Pediatr Hematol Oncol. 2021 Oct 1; 43: e946-e950.
Giver J, Dunn AL, Sankar A, Stanek J, Monda K, Canini J, Kerlin BA, Rodriguez V. Drive-through Anticoagulation Clinic During The COVID-19 Pandemic. J Nurse Pract. 2021 Sep 8;
Bakeer N, Dover S, Babyn P, Feldman BM, von Drygalski A, Doria AS, Ignas DM, Abad A, Bailey C, Beggs I, Chang EY, Dunn A, Funk S, Gibikote S, Goddard N, Hilliard P, Keshava SN, Kruse-Jarres R, Li Y, Lobet S, Manco-Johnson M, Martinoli C, O'Donnell JS, Papakonstantinou O, Pergantou H, Poonnoose P, Querol F, Srivastava A, Steiner B, Strike K, Timmer M, Tyrrell PN, Vidarsson L, Blanchette VS. Musculoskeletal ultrasound in hemophilia: Results and recommendations from a global survey and consensus meeting. Res Pract Thromb Haemost. 2021 Jul; 5: e12531.
Aquino CC, Borg Debono V, Germini F, Pete D, Kempton CL, Young G, Sidonio R, Croteau SE, Dunn AL, Key NS, Iorio A. Outcomes for studies assessing the efficacy of hemostatic therapies in persons with congenital bleeding disorders. Haemophilia. 2021 Mar; 27: 211-220.
Kuhn AK, Saini S, Stanek J, Dunn A, Kumar R. Unfractionated heparin using actual body weight without dose capping in obese pediatric patients-Subgroup analysis from an observational cohort study. Pediatr Blood Cancer. 2021 Mar; 68: e28872.
Abdelghani E, Dawson J, Zajo K, Hallam M, Dunn A, Kumar R. Fibrinogen Columbus III: A novel c.963del frameshift mutation in the FGG gene resulting in hypofibrinogenemia with a bleeding phenotype. Pediatr Blood Cancer. 2021 Mar; 68: e28713.
Konkle BA, Quon DV, Raffini L, Recht M, Radulescu VC, Carpenter SL, Dunn AL, Lu M, Watt M. A Prospective Observational Study of Antihemophilic Factor (Recombinant) Prophylaxis Related to Physical Activity Levels in Patients with Hemophilia A in the United States (SPACE). J Blood Med. 2021; 12: 883-896.
Davis KA, Stanek JR, Dunn AL. Screening urinalysis demonstrates that haematuria is a frequent finding in persons with haemophilia treated at a paediatric haemophilia treatment centre. Haemophilia. 2019 Jul 10;
Saini S, Folta AN, Harsh KL, Stanek JR, Dunn AL, O'Brien SH, Kumar R. Anti-Factor Xa-Based Monitoring of Unfractionated Heparin: Clinical Outcomes in a Pediatric Cohort. J Pediatr. 2019 Jun; 209: 212-219.e1.
Drayton Jackson M, Bartman T, McGinniss J, Widener P, Dunn AL. Optimizing patient flow in a multidisciplinary haemophilia clinic using quality improvement methodology. Haemophilia. 2019 May 29;
Kumar R, Dawson J, Varga E, Canini JT, Monda KL, Dunn AL. Fibrinogen Columbus II: A novel c.1075G>T mutation in the FGG gene causing hypodysfibrinogenemia and thrombosis in an adolescent male. Pediatr Blood Cancer. 2019 May 27; e27832.
Sharma R, Woods GM, Creary S, O'Brien S, Stanek J, Hor K, Gallagher C, Dunn AL, Kumar R. Impact of erythrocytapheresis on natural anticoagulant levels in children with sickle cell disease: A pilot study. Pediatr Blood Cancer. 2019 Apr; 66: e27588.
Drayton Jackson M, Dunn MW, Storey MA, Dunn AL. Increasing optimal coagulation factor dosing in the paediatric emergency department: A quality improvement study. Haemophilia. 2019 Mar; 25: 258-263.
Saini S, Croteau SE, Horling FM, Dunn AL. Factor IX inhibitors: Clinical and laboratory profiles of two patients with severe haemophilia B. Haemophilia. 2019 Mar; 25: e126-e129.
Dunn A, Patterson J, Biega CF, Grishchenko A, Luna J, Stanek JR, Strouse R. A Novel Clinician-Orchestrated Virtual Reality Platform for Distraction During Pediatric Intravenous Procedures in Children With Hemophilia: Randomized Controlled Trial. JMIR Serious Games. 2019 Jan 9; 7: e10902.
Young G, Callaghan M, Dunn A, Kruse-Jarres R, Pipe S. Emicizumab for hemophilia A with factor VIII inhibitors. Expert Rev Hematol. 2018 Nov; 11: 835-846.
Bergin SM, Dunn AL, Smith LGF, Drapeau AI. Management of hydrocephalus in infants with severe hemophilia A: report of 2 cases. J Neurosurg Pediatr. 2018 Nov 2; 23: 159-163.
Drayton Jackson M, O'Brien SH, Stanek J, Dunn AL, Kerlin BA. Inpatient Health Care Utilization in Children With Hemophilia Before and After the Joint Outcome Study Publication. J Pediatr Hematol Oncol. 2018 Oct 18;
Croteau SE, Callaghan MU, Davis J, Dunn AL, Guerrera M, Khan O, Neufeld EJ, Raffini LJ, Recht M, Wang M, Iorio A. Focusing in on use of pharmacokinetic profiles in routine hemophilia care. Res Pract Thromb Haemost. 2018 Jul; 2: 607-614.
View More Publications
Education
Date of Appointment at Nationwide Children’s Hospital: 01/24/2014
Board Certifications
Pediatric Hematology Oncology Pediatrics
Fellowship
Emory University/Children’s Healthcare of Atlanta
Date Completed: 06/30/2000
Residency
Emory University/Children’s Healthcare of Atlanta
Date Completed: 06/30/1997
Medical School
Wright State University School of Medicine
Date Completed: 05/31/1994
Contact Information
Pediatrics
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)
Contact Information
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
PediatricsHematology & Oncology700 Children’s DrColumbus, OH 43205 (map)
Learn more about Amy L. Dunn
Biography
Dr Dunn received her medical degree from Wright State University School of Medicine in Dayton, Ohio and completed her pediatric and pediatric hematology/oncology training at Emory University in Atlanta, Georgia. She is an Associate Professor of Pediatrics at Nationwide Children's Hospital/Ohio State University where she is the Director of Pediatric Hematology and directs the Hemophilia Treatment Center.
She is a member of various professional associations including the American Society of Hematology, World Federation of Hemophilia, The International Society of Thrombosis and Hemostasis, the International Pediatric Hemophilia Network, the International Prophylaxis Study Group and the Hemophilia and Thrombosis Research Society (HTRS). Dr Dunn has served as a reviewer for hematologic journals including the Journal of Pediatric Blood and Cancer, the Journal of Thrombosis and Hemostasis, Blood and Haemophilia. She has published numerous peer-reviewed articles, abstracts, and textbook chapters. In addition, she has given many presentations at national and international medical conferences and has received awards that include US News and World Report Top Doctors and the Atlanta Business Chronicle Healthcare Hero for Healthcare Innovation.
Patient Care
Locations
Westerville Sports Medicine and Orthopedic Center
Main Campus of Nationwide Children’s Hospital
Academic and Clinical Areas
Hemostasis and Thrombosis Center
Director
Hematology/Oncology & BMT
Director
Hematology, Oncology and BMT Fellowship
Faculty
Pediatric Hemostasis-Thrombosis Fellowship
Faculty
Primary Department
Pediatrics
Primary Section
Hematology & Oncology
Awards, Honors & Organizations
Listed, Best Doctors in America
Research
Publications
Pierce GF, Adediran M, Diop S, Dunn AL, El Ekiaby M, Kaczmarek R, Konkle BA, Pipe SW, Skinner MW, Valentino LA, Robinson F, Ampartzidis G, Martin J, Haffar A. Achieving access to haemophilia care in low-income and lower-middle-income countries: expanded Humanitarian Aid Program of the World Federation of Hemophilia after 5 years. Lancet Haematol. 2022 Sep; 9: e689-e697.
Kumar R, Dunn A, Schneiderman JE, Gonzales A, Bouskill V, Widener P, Stanek J, Pluthero FG, Waller A, Tarango C, Ahuja S, Kerlin BA, Kahr WH, Rand ML, Lillicrap D, Carcao M. Moderate-intensity aerobic exercise versus desmopressin in adolescent males with mild hemophilia A: a randomized trial. Blood. 2022 Jul 15;
Escobar M, Dunn A, Quon D, Trzaskoma B, Lee L, Ko RH, Carpenter SL. A phase IV, multicentre, open-label study of emicizumab prophylaxis in people with haemophilia A with or without FVIII inhibitors undergoing minor surgical procedures. Haemophilia. 2022 May 5;
Pipe SW, Hermans C, Chitlur M, Carcao M, Castaman G, Davis JA, Ducore J, Dunn AL, Escobar M, Journeycake J, Khan O, Mahlangu J, Meeks SL, Mitha IH, Négrier C, Nowak-Göttl U, Recht M, Chrisentery-Singleton T, Stasyshyn O, Vilchevska KV, Martinez LV, Wang M, Windyga J, Young G, Alexander WA, Bonzo D, Macie C, Mitchell IS, Sauty E, Wilkinson TA, Shapiro AD. Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors. Haemophilia. 2022 Apr 27;
Königs C, Ozelo MC, Dunn A, Kulkarni R, Nolan B, Brown SA, Schiavulli M, Gunawardena S, Mukhopadhyay S, Jayawardene D, Winding B, Carcao M. First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results. Blood. 2022 Apr 12;
Rodriguez V, Stanek J, Kerlin BA, Dunn AL. Andexanet Alfa Versus Prothrombin Complex Concentrates/Blood Products as Apixaban/Rivaroxaban Reversal Agents: A Survey Among Pediatric Hematologists. Clin Appl Thromb Hemost. 2022 Jan-Dec; 28: 10760296221078842.
Wysocki EL, Kuhn A, Steinbrenner J, Tyrrell L, Abdel-Rasoul M, Dunn A, Cloyd C. Enoxaparin Dose Requirements to Achieve Therapeutic Low-molecular-weight Heparin Anti-factor Xa Levels in Infants and Young Children. J Pediatr Hematol Oncol. 2021 Oct 1; 43: e946-e950.
Giver J, Dunn AL, Sankar A, Stanek J, Monda K, Canini J, Kerlin BA, Rodriguez V. Drive-through Anticoagulation Clinic During The COVID-19 Pandemic. J Nurse Pract. 2021 Sep 8;
Bakeer N, Dover S, Babyn P, Feldman BM, von Drygalski A, Doria AS, Ignas DM, Abad A, Bailey C, Beggs I, Chang EY, Dunn A, Funk S, Gibikote S, Goddard N, Hilliard P, Keshava SN, Kruse-Jarres R, Li Y, Lobet S, Manco-Johnson M, Martinoli C, O'Donnell JS, Papakonstantinou O, Pergantou H, Poonnoose P, Querol F, Srivastava A, Steiner B, Strike K, Timmer M, Tyrrell PN, Vidarsson L, Blanchette VS. Musculoskeletal ultrasound in hemophilia: Results and recommendations from a global survey and consensus meeting. Res Pract Thromb Haemost. 2021 Jul; 5: e12531.
Aquino CC, Borg Debono V, Germini F, Pete D, Kempton CL, Young G, Sidonio R, Croteau SE, Dunn AL, Key NS, Iorio A. Outcomes for studies assessing the efficacy of hemostatic therapies in persons with congenital bleeding disorders. Haemophilia. 2021 Mar; 27: 211-220.
Kuhn AK, Saini S, Stanek J, Dunn A, Kumar R. Unfractionated heparin using actual body weight without dose capping in obese pediatric patients-Subgroup analysis from an observational cohort study. Pediatr Blood Cancer. 2021 Mar; 68: e28872.
Abdelghani E, Dawson J, Zajo K, Hallam M, Dunn A, Kumar R. Fibrinogen Columbus III: A novel c.963del frameshift mutation in the FGG gene resulting in hypofibrinogenemia with a bleeding phenotype. Pediatr Blood Cancer. 2021 Mar; 68: e28713.
Konkle BA, Quon DV, Raffini L, Recht M, Radulescu VC, Carpenter SL, Dunn AL, Lu M, Watt M. A Prospective Observational Study of Antihemophilic Factor (Recombinant) Prophylaxis Related to Physical Activity Levels in Patients with Hemophilia A in the United States (SPACE). J Blood Med. 2021; 12: 883-896.
Davis KA, Stanek JR, Dunn AL. Screening urinalysis demonstrates that haematuria is a frequent finding in persons with haemophilia treated at a paediatric haemophilia treatment centre. Haemophilia. 2019 Jul 10;
Saini S, Folta AN, Harsh KL, Stanek JR, Dunn AL, O'Brien SH, Kumar R. Anti-Factor Xa-Based Monitoring of Unfractionated Heparin: Clinical Outcomes in a Pediatric Cohort. J Pediatr. 2019 Jun; 209: 212-219.e1.
Drayton Jackson M, Bartman T, McGinniss J, Widener P, Dunn AL. Optimizing patient flow in a multidisciplinary haemophilia clinic using quality improvement methodology. Haemophilia. 2019 May 29;
Kumar R, Dawson J, Varga E, Canini JT, Monda KL, Dunn AL. Fibrinogen Columbus II: A novel c.1075G>T mutation in the FGG gene causing hypodysfibrinogenemia and thrombosis in an adolescent male. Pediatr Blood Cancer. 2019 May 27; e27832.
Sharma R, Woods GM, Creary S, O'Brien S, Stanek J, Hor K, Gallagher C, Dunn AL, Kumar R. Impact of erythrocytapheresis on natural anticoagulant levels in children with sickle cell disease: A pilot study. Pediatr Blood Cancer. 2019 Apr; 66: e27588.
Drayton Jackson M, Dunn MW, Storey MA, Dunn AL. Increasing optimal coagulation factor dosing in the paediatric emergency department: A quality improvement study. Haemophilia. 2019 Mar; 25: 258-263.
Saini S, Croteau SE, Horling FM, Dunn AL. Factor IX inhibitors: Clinical and laboratory profiles of two patients with severe haemophilia B. Haemophilia. 2019 Mar; 25: e126-e129.
Dunn A, Patterson J, Biega CF, Grishchenko A, Luna J, Stanek JR, Strouse R. A Novel Clinician-Orchestrated Virtual Reality Platform for Distraction During Pediatric Intravenous Procedures in Children With Hemophilia: Randomized Controlled Trial. JMIR Serious Games. 2019 Jan 9; 7: e10902.
Young G, Callaghan M, Dunn A, Kruse-Jarres R, Pipe S. Emicizumab for hemophilia A with factor VIII inhibitors. Expert Rev Hematol. 2018 Nov; 11: 835-846.
Bergin SM, Dunn AL, Smith LGF, Drapeau AI. Management of hydrocephalus in infants with severe hemophilia A: report of 2 cases. J Neurosurg Pediatr. 2018 Nov 2; 23: 159-163.
Drayton Jackson M, O'Brien SH, Stanek J, Dunn AL, Kerlin BA. Inpatient Health Care Utilization in Children With Hemophilia Before and After the Joint Outcome Study Publication. J Pediatr Hematol Oncol. 2018 Oct 18;
Croteau SE, Callaghan MU, Davis J, Dunn AL, Guerrera M, Khan O, Neufeld EJ, Raffini LJ, Recht M, Wang M, Iorio A. Focusing in on use of pharmacokinetic profiles in routine hemophilia care. Res Pract Thromb Haemost. 2018 Jul; 2: 607-614.
View More Publications
Education
Date of Appointment at Nationwide Children’s Hospital: 01/24/2014
Board Certifications
Pediatric Hematology Oncology Pediatrics
Fellowship
Emory University/Children’s Healthcare of Atlanta
Date Completed: 06/30/2000
Residency
Emory University/Children’s Healthcare of Atlanta
Date Completed: 06/30/1997
Medical School
Wright State University School of Medicine
Date Completed: 05/31/1994
Contact Information
Pediatrics
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)
Contact Information
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
PediatricsHematology & Oncology700 Children’s DrColumbus, OH 43205 (map)
Learn more about Amy L. Dunn
Contact Information
- Call us at:
- (614) 722-3550
- Fax us at:
- (614) 722-3369
- PediatricsHematology & Oncology700 Children’s DrColumbus, OH 43205 (map)
Learn more about Amy L. Dunn
Biography
Dr Dunn received her medical degree from Wright State University School of Medicine in Dayton, Ohio and completed her pediatric and pediatric hematology/oncology training at Emory University in Atlanta, Georgia. She is an Associate Professor of Pediatrics at Nationwide Children's Hospital/Ohio State University where she is the Director of Pediatric Hematology and directs the Hemophilia Treatment Center.
She is a member of various professional associations including the American Society of Hematology, World Federation of Hemophilia, The International Society of Thrombosis and Hemostasis, the International Pediatric Hemophilia Network, the International Prophylaxis Study Group and the Hemophilia and Thrombosis Research Society (HTRS). Dr Dunn has served as a reviewer for hematologic journals including the Journal of Pediatric Blood and Cancer, the Journal of Thrombosis and Hemostasis, Blood and Haemophilia. She has published numerous peer-reviewed articles, abstracts, and textbook chapters. In addition, she has given many presentations at national and international medical conferences and has received awards that include US News and World Report Top Doctors and the Atlanta Business Chronicle Healthcare Hero for Healthcare Innovation.
Biography
Dr Dunn received her medical degree from Wright State University School of Medicine in Dayton, Ohio and completed her pediatric and pediatric hematology/oncology training at Emory University in Atlanta, Georgia. She is an Associate Professor of Pediatrics at Nationwide Children's Hospital/Ohio State University where she is the Director of Pediatric Hematology and directs the Hemophilia Treatment Center.
She is a member of various professional associations including the American Society of Hematology, World Federation of Hemophilia, The International Society of Thrombosis and Hemostasis, the International Pediatric Hemophilia Network, the International Prophylaxis Study Group and the Hemophilia and Thrombosis Research Society (HTRS). Dr Dunn has served as a reviewer for hematologic journals including the Journal of Pediatric Blood and Cancer, the Journal of Thrombosis and Hemostasis, Blood and Haemophilia. She has published numerous peer-reviewed articles, abstracts, and textbook chapters. In addition, she has given many presentations at national and international medical conferences and has received awards that include US News and World Report Top Doctors and the Atlanta Business Chronicle Healthcare Hero for Healthcare Innovation.
Biography
Dr Dunn received her medical degree from Wright State University School of Medicine in Dayton, Ohio and completed her pediatric and pediatric hematology/oncology training at Emory University in Atlanta, Georgia. She is an Associate Professor of Pediatrics at Nationwide Children's Hospital/Ohio State University where she is the Director of Pediatric Hematology and directs the Hemophilia Treatment Center.
She is a member of various professional associations including the American Society of Hematology, World Federation of Hemophilia, The International Society of Thrombosis and Hemostasis, the International Pediatric Hemophilia Network, the International Prophylaxis Study Group and the Hemophilia and Thrombosis Research Society (HTRS). Dr Dunn has served as a reviewer for hematologic journals including the Journal of Pediatric Blood and Cancer, the Journal of Thrombosis and Hemostasis, Blood and Haemophilia. She has published numerous peer-reviewed articles, abstracts, and textbook chapters. In addition, she has given many presentations at national and international medical conferences and has received awards that include US News and World Report Top Doctors and the Atlanta Business Chronicle Healthcare Hero for Healthcare Innovation.
Dr Dunn received her medical degree from Wright State University School of Medicine in Dayton, Ohio and completed her pediatric and pediatric hematology/oncology training at Emory University in Atlanta, Georgia. She is an Associate Professor of Pediatrics at Nationwide Children's Hospital/Ohio State University where she is the Director of Pediatric Hematology and directs the Hemophilia Treatment Center.
She is a member of various professional associations including the American Society of Hematology, World Federation of Hemophilia, The International Society of Thrombosis and Hemostasis, the International Pediatric Hemophilia Network, the International Prophylaxis Study Group and the Hemophilia and Thrombosis Research Society (HTRS). Dr Dunn has served as a reviewer for hematologic journals including the Journal of Pediatric Blood and Cancer, the Journal of Thrombosis and Hemostasis, Blood and Haemophilia. She has published numerous peer-reviewed articles, abstracts, and textbook chapters. In addition, she has given many presentations at national and international medical conferences and has received awards that include US News and World Report Top Doctors and the Atlanta Business Chronicle Healthcare Hero for Healthcare Innovation.
Patient Care
Locations
Westerville Sports Medicine and Orthopedic Center
Main Campus of Nationwide Children’s Hospital
Patient Care
Locations
Westerville Sports Medicine and Orthopedic Center
Main Campus of Nationwide Children’s Hospital
Patient Care
Locations
Westerville Sports Medicine and Orthopedic Center
Main Campus of Nationwide Children’s Hospital
Locations
Westerville Sports Medicine and Orthopedic Center
Main Campus of Nationwide Children’s Hospital
Locations
Westerville Sports Medicine and Orthopedic Center
Main Campus of Nationwide Children’s Hospital
Locations
Westerville Sports Medicine and Orthopedic Center
Main Campus of Nationwide Children’s Hospital
- Westerville Sports Medicine and Orthopedic Center
- Main Campus of Nationwide Children’s Hospital
Academic and Clinical Areas
Hemostasis and Thrombosis Center
Director
Hematology/Oncology & BMT
Director
Hematology, Oncology and BMT Fellowship
Faculty
Pediatric Hemostasis-Thrombosis Fellowship
Faculty
Primary Department
Pediatrics
Primary Section
Hematology & Oncology
Academic and Clinical Areas
Hemostasis and Thrombosis Center
Director
Hematology/Oncology & BMT
Director
Hematology, Oncology and BMT Fellowship
Faculty
Pediatric Hemostasis-Thrombosis Fellowship
Faculty
Primary Department
Pediatrics
Primary Section
Hematology & Oncology
Academic and Clinical Areas
Hemostasis and Thrombosis Center
Director
Hematology/Oncology & BMT
Director
Hematology, Oncology and BMT Fellowship
Faculty
Pediatric Hemostasis-Thrombosis Fellowship
Faculty
Primary Department
Pediatrics
Primary Section
Hematology & Oncology
Hemostasis and Thrombosis Center
Director
Hematology/Oncology & BMT
Director
Hematology, Oncology and BMT Fellowship
Faculty
Pediatric Hemostasis-Thrombosis Fellowship
Faculty
Primary Department
Pediatrics
Primary Section
Hematology & Oncology
- Hemostasis and Thrombosis Center
- Director
- Hematology/Oncology & BMT
- Director
- Hematology, Oncology and BMT Fellowship
- Faculty
- Pediatric Hemostasis-Thrombosis Fellowship
- Faculty
- Primary Department
- Pediatrics
- Primary Section
- Hematology & Oncology
Awards, Honors & Organizations
Listed, Best Doctors in America
Awards, Honors & Organizations
Listed, Best Doctors in America
Awards, Honors & Organizations
Listed, Best Doctors in America
Listed, Best Doctors in America
- Listed, Best Doctors in America
Research
Publications
Pierce GF, Adediran M, Diop S, Dunn AL, El Ekiaby M, Kaczmarek R, Konkle BA, Pipe SW, Skinner MW, Valentino LA, Robinson F, Ampartzidis G, Martin J, Haffar A. Achieving access to haemophilia care in low-income and lower-middle-income countries: expanded Humanitarian Aid Program of the World Federation of Hemophilia after 5 years. Lancet Haematol. 2022 Sep; 9: e689-e697.
Kumar R, Dunn A, Schneiderman JE, Gonzales A, Bouskill V, Widener P, Stanek J, Pluthero FG, Waller A, Tarango C, Ahuja S, Kerlin BA, Kahr WH, Rand ML, Lillicrap D, Carcao M. Moderate-intensity aerobic exercise versus desmopressin in adolescent males with mild hemophilia A: a randomized trial. Blood. 2022 Jul 15;
Escobar M, Dunn A, Quon D, Trzaskoma B, Lee L, Ko RH, Carpenter SL. A phase IV, multicentre, open-label study of emicizumab prophylaxis in people with haemophilia A with or without FVIII inhibitors undergoing minor surgical procedures. Haemophilia. 2022 May 5;
Pipe SW, Hermans C, Chitlur M, Carcao M, Castaman G, Davis JA, Ducore J, Dunn AL, Escobar M, Journeycake J, Khan O, Mahlangu J, Meeks SL, Mitha IH, Négrier C, Nowak-Göttl U, Recht M, Chrisentery-Singleton T, Stasyshyn O, Vilchevska KV, Martinez LV, Wang M, Windyga J, Young G, Alexander WA, Bonzo D, Macie C, Mitchell IS, Sauty E, Wilkinson TA, Shapiro AD. Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors. Haemophilia. 2022 Apr 27;
Königs C, Ozelo MC, Dunn A, Kulkarni R, Nolan B, Brown SA, Schiavulli M, Gunawardena S, Mukhopadhyay S, Jayawardene D, Winding B, Carcao M. First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results. Blood. 2022 Apr 12;
Rodriguez V, Stanek J, Kerlin BA, Dunn AL. Andexanet Alfa Versus Prothrombin Complex Concentrates/Blood Products as Apixaban/Rivaroxaban Reversal Agents: A Survey Among Pediatric Hematologists. Clin Appl Thromb Hemost. 2022 Jan-Dec; 28: 10760296221078842.
Wysocki EL, Kuhn A, Steinbrenner J, Tyrrell L, Abdel-Rasoul M, Dunn A, Cloyd C. Enoxaparin Dose Requirements to Achieve Therapeutic Low-molecular-weight Heparin Anti-factor Xa Levels in Infants and Young Children. J Pediatr Hematol Oncol. 2021 Oct 1; 43: e946-e950.
Giver J, Dunn AL, Sankar A, Stanek J, Monda K, Canini J, Kerlin BA, Rodriguez V. Drive-through Anticoagulation Clinic During The COVID-19 Pandemic. J Nurse Pract. 2021 Sep 8;
Bakeer N, Dover S, Babyn P, Feldman BM, von Drygalski A, Doria AS, Ignas DM, Abad A, Bailey C, Beggs I, Chang EY, Dunn A, Funk S, Gibikote S, Goddard N, Hilliard P, Keshava SN, Kruse-Jarres R, Li Y, Lobet S, Manco-Johnson M, Martinoli C, O'Donnell JS, Papakonstantinou O, Pergantou H, Poonnoose P, Querol F, Srivastava A, Steiner B, Strike K, Timmer M, Tyrrell PN, Vidarsson L, Blanchette VS. Musculoskeletal ultrasound in hemophilia: Results and recommendations from a global survey and consensus meeting. Res Pract Thromb Haemost. 2021 Jul; 5: e12531.
Aquino CC, Borg Debono V, Germini F, Pete D, Kempton CL, Young G, Sidonio R, Croteau SE, Dunn AL, Key NS, Iorio A. Outcomes for studies assessing the efficacy of hemostatic therapies in persons with congenital bleeding disorders. Haemophilia. 2021 Mar; 27: 211-220.
Kuhn AK, Saini S, Stanek J, Dunn A, Kumar R. Unfractionated heparin using actual body weight without dose capping in obese pediatric patients-Subgroup analysis from an observational cohort study. Pediatr Blood Cancer. 2021 Mar; 68: e28872.
Abdelghani E, Dawson J, Zajo K, Hallam M, Dunn A, Kumar R. Fibrinogen Columbus III: A novel c.963del frameshift mutation in the FGG gene resulting in hypofibrinogenemia with a bleeding phenotype. Pediatr Blood Cancer. 2021 Mar; 68: e28713.
Konkle BA, Quon DV, Raffini L, Recht M, Radulescu VC, Carpenter SL, Dunn AL, Lu M, Watt M. A Prospective Observational Study of Antihemophilic Factor (Recombinant) Prophylaxis Related to Physical Activity Levels in Patients with Hemophilia A in the United States (SPACE). J Blood Med. 2021; 12: 883-896.
Davis KA, Stanek JR, Dunn AL. Screening urinalysis demonstrates that haematuria is a frequent finding in persons with haemophilia treated at a paediatric haemophilia treatment centre. Haemophilia. 2019 Jul 10;
Saini S, Folta AN, Harsh KL, Stanek JR, Dunn AL, O'Brien SH, Kumar R. Anti-Factor Xa-Based Monitoring of Unfractionated Heparin: Clinical Outcomes in a Pediatric Cohort. J Pediatr. 2019 Jun; 209: 212-219.e1.
Drayton Jackson M, Bartman T, McGinniss J, Widener P, Dunn AL. Optimizing patient flow in a multidisciplinary haemophilia clinic using quality improvement methodology. Haemophilia. 2019 May 29;
Kumar R, Dawson J, Varga E, Canini JT, Monda KL, Dunn AL. Fibrinogen Columbus II: A novel c.1075G>T mutation in the FGG gene causing hypodysfibrinogenemia and thrombosis in an adolescent male. Pediatr Blood Cancer. 2019 May 27; e27832.
Sharma R, Woods GM, Creary S, O'Brien S, Stanek J, Hor K, Gallagher C, Dunn AL, Kumar R. Impact of erythrocytapheresis on natural anticoagulant levels in children with sickle cell disease: A pilot study. Pediatr Blood Cancer. 2019 Apr; 66: e27588.
Drayton Jackson M, Dunn MW, Storey MA, Dunn AL. Increasing optimal coagulation factor dosing in the paediatric emergency department: A quality improvement study. Haemophilia. 2019 Mar; 25: 258-263.
Saini S, Croteau SE, Horling FM, Dunn AL. Factor IX inhibitors: Clinical and laboratory profiles of two patients with severe haemophilia B. Haemophilia. 2019 Mar; 25: e126-e129.
Dunn A, Patterson J, Biega CF, Grishchenko A, Luna J, Stanek JR, Strouse R. A Novel Clinician-Orchestrated Virtual Reality Platform for Distraction During Pediatric Intravenous Procedures in Children With Hemophilia: Randomized Controlled Trial. JMIR Serious Games. 2019 Jan 9; 7: e10902.
Young G, Callaghan M, Dunn A, Kruse-Jarres R, Pipe S. Emicizumab for hemophilia A with factor VIII inhibitors. Expert Rev Hematol. 2018 Nov; 11: 835-846.
Bergin SM, Dunn AL, Smith LGF, Drapeau AI. Management of hydrocephalus in infants with severe hemophilia A: report of 2 cases. J Neurosurg Pediatr. 2018 Nov 2; 23: 159-163.
Drayton Jackson M, O'Brien SH, Stanek J, Dunn AL, Kerlin BA. Inpatient Health Care Utilization in Children With Hemophilia Before and After the Joint Outcome Study Publication. J Pediatr Hematol Oncol. 2018 Oct 18;
Croteau SE, Callaghan MU, Davis J, Dunn AL, Guerrera M, Khan O, Neufeld EJ, Raffini LJ, Recht M, Wang M, Iorio A. Focusing in on use of pharmacokinetic profiles in routine hemophilia care. Res Pract Thromb Haemost. 2018 Jul; 2: 607-614.
View More Publications
Research
Publications
Pierce GF, Adediran M, Diop S, Dunn AL, El Ekiaby M, Kaczmarek R, Konkle BA, Pipe SW, Skinner MW, Valentino LA, Robinson F, Ampartzidis G, Martin J, Haffar A. Achieving access to haemophilia care in low-income and lower-middle-income countries: expanded Humanitarian Aid Program of the World Federation of Hemophilia after 5 years. Lancet Haematol. 2022 Sep; 9: e689-e697.
Kumar R, Dunn A, Schneiderman JE, Gonzales A, Bouskill V, Widener P, Stanek J, Pluthero FG, Waller A, Tarango C, Ahuja S, Kerlin BA, Kahr WH, Rand ML, Lillicrap D, Carcao M. Moderate-intensity aerobic exercise versus desmopressin in adolescent males with mild hemophilia A: a randomized trial. Blood. 2022 Jul 15;
Escobar M, Dunn A, Quon D, Trzaskoma B, Lee L, Ko RH, Carpenter SL. A phase IV, multicentre, open-label study of emicizumab prophylaxis in people with haemophilia A with or without FVIII inhibitors undergoing minor surgical procedures. Haemophilia. 2022 May 5;
Pipe SW, Hermans C, Chitlur M, Carcao M, Castaman G, Davis JA, Ducore J, Dunn AL, Escobar M, Journeycake J, Khan O, Mahlangu J, Meeks SL, Mitha IH, Négrier C, Nowak-Göttl U, Recht M, Chrisentery-Singleton T, Stasyshyn O, Vilchevska KV, Martinez LV, Wang M, Windyga J, Young G, Alexander WA, Bonzo D, Macie C, Mitchell IS, Sauty E, Wilkinson TA, Shapiro AD. Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors. Haemophilia. 2022 Apr 27;
Königs C, Ozelo MC, Dunn A, Kulkarni R, Nolan B, Brown SA, Schiavulli M, Gunawardena S, Mukhopadhyay S, Jayawardene D, Winding B, Carcao M. First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results. Blood. 2022 Apr 12;
Rodriguez V, Stanek J, Kerlin BA, Dunn AL. Andexanet Alfa Versus Prothrombin Complex Concentrates/Blood Products as Apixaban/Rivaroxaban Reversal Agents: A Survey Among Pediatric Hematologists. Clin Appl Thromb Hemost. 2022 Jan-Dec; 28: 10760296221078842.
Wysocki EL, Kuhn A, Steinbrenner J, Tyrrell L, Abdel-Rasoul M, Dunn A, Cloyd C. Enoxaparin Dose Requirements to Achieve Therapeutic Low-molecular-weight Heparin Anti-factor Xa Levels in Infants and Young Children. J Pediatr Hematol Oncol. 2021 Oct 1; 43: e946-e950.
Giver J, Dunn AL, Sankar A, Stanek J, Monda K, Canini J, Kerlin BA, Rodriguez V. Drive-through Anticoagulation Clinic During The COVID-19 Pandemic. J Nurse Pract. 2021 Sep 8;
Bakeer N, Dover S, Babyn P, Feldman BM, von Drygalski A, Doria AS, Ignas DM, Abad A, Bailey C, Beggs I, Chang EY, Dunn A, Funk S, Gibikote S, Goddard N, Hilliard P, Keshava SN, Kruse-Jarres R, Li Y, Lobet S, Manco-Johnson M, Martinoli C, O'Donnell JS, Papakonstantinou O, Pergantou H, Poonnoose P, Querol F, Srivastava A, Steiner B, Strike K, Timmer M, Tyrrell PN, Vidarsson L, Blanchette VS. Musculoskeletal ultrasound in hemophilia: Results and recommendations from a global survey and consensus meeting. Res Pract Thromb Haemost. 2021 Jul; 5: e12531.
Aquino CC, Borg Debono V, Germini F, Pete D, Kempton CL, Young G, Sidonio R, Croteau SE, Dunn AL, Key NS, Iorio A. Outcomes for studies assessing the efficacy of hemostatic therapies in persons with congenital bleeding disorders. Haemophilia. 2021 Mar; 27: 211-220.
Kuhn AK, Saini S, Stanek J, Dunn A, Kumar R. Unfractionated heparin using actual body weight without dose capping in obese pediatric patients-Subgroup analysis from an observational cohort study. Pediatr Blood Cancer. 2021 Mar; 68: e28872.
Abdelghani E, Dawson J, Zajo K, Hallam M, Dunn A, Kumar R. Fibrinogen Columbus III: A novel c.963del frameshift mutation in the FGG gene resulting in hypofibrinogenemia with a bleeding phenotype. Pediatr Blood Cancer. 2021 Mar; 68: e28713.
Konkle BA, Quon DV, Raffini L, Recht M, Radulescu VC, Carpenter SL, Dunn AL, Lu M, Watt M. A Prospective Observational Study of Antihemophilic Factor (Recombinant) Prophylaxis Related to Physical Activity Levels in Patients with Hemophilia A in the United States (SPACE). J Blood Med. 2021; 12: 883-896.
Davis KA, Stanek JR, Dunn AL. Screening urinalysis demonstrates that haematuria is a frequent finding in persons with haemophilia treated at a paediatric haemophilia treatment centre. Haemophilia. 2019 Jul 10;
Saini S, Folta AN, Harsh KL, Stanek JR, Dunn AL, O'Brien SH, Kumar R. Anti-Factor Xa-Based Monitoring of Unfractionated Heparin: Clinical Outcomes in a Pediatric Cohort. J Pediatr. 2019 Jun; 209: 212-219.e1.
Drayton Jackson M, Bartman T, McGinniss J, Widener P, Dunn AL. Optimizing patient flow in a multidisciplinary haemophilia clinic using quality improvement methodology. Haemophilia. 2019 May 29;
Kumar R, Dawson J, Varga E, Canini JT, Monda KL, Dunn AL. Fibrinogen Columbus II: A novel c.1075G>T mutation in the FGG gene causing hypodysfibrinogenemia and thrombosis in an adolescent male. Pediatr Blood Cancer. 2019 May 27; e27832.
Sharma R, Woods GM, Creary S, O'Brien S, Stanek J, Hor K, Gallagher C, Dunn AL, Kumar R. Impact of erythrocytapheresis on natural anticoagulant levels in children with sickle cell disease: A pilot study. Pediatr Blood Cancer. 2019 Apr; 66: e27588.
Drayton Jackson M, Dunn MW, Storey MA, Dunn AL. Increasing optimal coagulation factor dosing in the paediatric emergency department: A quality improvement study. Haemophilia. 2019 Mar; 25: 258-263.
Saini S, Croteau SE, Horling FM, Dunn AL. Factor IX inhibitors: Clinical and laboratory profiles of two patients with severe haemophilia B. Haemophilia. 2019 Mar; 25: e126-e129.
Dunn A, Patterson J, Biega CF, Grishchenko A, Luna J, Stanek JR, Strouse R. A Novel Clinician-Orchestrated Virtual Reality Platform for Distraction During Pediatric Intravenous Procedures in Children With Hemophilia: Randomized Controlled Trial. JMIR Serious Games. 2019 Jan 9; 7: e10902.
Young G, Callaghan M, Dunn A, Kruse-Jarres R, Pipe S. Emicizumab for hemophilia A with factor VIII inhibitors. Expert Rev Hematol. 2018 Nov; 11: 835-846.
Bergin SM, Dunn AL, Smith LGF, Drapeau AI. Management of hydrocephalus in infants with severe hemophilia A: report of 2 cases. J Neurosurg Pediatr. 2018 Nov 2; 23: 159-163.
Drayton Jackson M, O'Brien SH, Stanek J, Dunn AL, Kerlin BA. Inpatient Health Care Utilization in Children With Hemophilia Before and After the Joint Outcome Study Publication. J Pediatr Hematol Oncol. 2018 Oct 18;
Croteau SE, Callaghan MU, Davis J, Dunn AL, Guerrera M, Khan O, Neufeld EJ, Raffini LJ, Recht M, Wang M, Iorio A. Focusing in on use of pharmacokinetic profiles in routine hemophilia care. Res Pract Thromb Haemost. 2018 Jul; 2: 607-614.
View More Publications
Research
Publications
Pierce GF, Adediran M, Diop S, Dunn AL, El Ekiaby M, Kaczmarek R, Konkle BA, Pipe SW, Skinner MW, Valentino LA, Robinson F, Ampartzidis G, Martin J, Haffar A. Achieving access to haemophilia care in low-income and lower-middle-income countries: expanded Humanitarian Aid Program of the World Federation of Hemophilia after 5 years. Lancet Haematol. 2022 Sep; 9: e689-e697.
Kumar R, Dunn A, Schneiderman JE, Gonzales A, Bouskill V, Widener P, Stanek J, Pluthero FG, Waller A, Tarango C, Ahuja S, Kerlin BA, Kahr WH, Rand ML, Lillicrap D, Carcao M. Moderate-intensity aerobic exercise versus desmopressin in adolescent males with mild hemophilia A: a randomized trial. Blood. 2022 Jul 15;
Escobar M, Dunn A, Quon D, Trzaskoma B, Lee L, Ko RH, Carpenter SL. A phase IV, multicentre, open-label study of emicizumab prophylaxis in people with haemophilia A with or without FVIII inhibitors undergoing minor surgical procedures. Haemophilia. 2022 May 5;
Pipe SW, Hermans C, Chitlur M, Carcao M, Castaman G, Davis JA, Ducore J, Dunn AL, Escobar M, Journeycake J, Khan O, Mahlangu J, Meeks SL, Mitha IH, Négrier C, Nowak-Göttl U, Recht M, Chrisentery-Singleton T, Stasyshyn O, Vilchevska KV, Martinez LV, Wang M, Windyga J, Young G, Alexander WA, Bonzo D, Macie C, Mitchell IS, Sauty E, Wilkinson TA, Shapiro AD. Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors. Haemophilia. 2022 Apr 27;
Königs C, Ozelo MC, Dunn A, Kulkarni R, Nolan B, Brown SA, Schiavulli M, Gunawardena S, Mukhopadhyay S, Jayawardene D, Winding B, Carcao M. First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results. Blood. 2022 Apr 12;
Rodriguez V, Stanek J, Kerlin BA, Dunn AL. Andexanet Alfa Versus Prothrombin Complex Concentrates/Blood Products as Apixaban/Rivaroxaban Reversal Agents: A Survey Among Pediatric Hematologists. Clin Appl Thromb Hemost. 2022 Jan-Dec; 28: 10760296221078842.
Wysocki EL, Kuhn A, Steinbrenner J, Tyrrell L, Abdel-Rasoul M, Dunn A, Cloyd C. Enoxaparin Dose Requirements to Achieve Therapeutic Low-molecular-weight Heparin Anti-factor Xa Levels in Infants and Young Children. J Pediatr Hematol Oncol. 2021 Oct 1; 43: e946-e950.
Giver J, Dunn AL, Sankar A, Stanek J, Monda K, Canini J, Kerlin BA, Rodriguez V. Drive-through Anticoagulation Clinic During The COVID-19 Pandemic. J Nurse Pract. 2021 Sep 8;
Bakeer N, Dover S, Babyn P, Feldman BM, von Drygalski A, Doria AS, Ignas DM, Abad A, Bailey C, Beggs I, Chang EY, Dunn A, Funk S, Gibikote S, Goddard N, Hilliard P, Keshava SN, Kruse-Jarres R, Li Y, Lobet S, Manco-Johnson M, Martinoli C, O'Donnell JS, Papakonstantinou O, Pergantou H, Poonnoose P, Querol F, Srivastava A, Steiner B, Strike K, Timmer M, Tyrrell PN, Vidarsson L, Blanchette VS. Musculoskeletal ultrasound in hemophilia: Results and recommendations from a global survey and consensus meeting. Res Pract Thromb Haemost. 2021 Jul; 5: e12531.
Aquino CC, Borg Debono V, Germini F, Pete D, Kempton CL, Young G, Sidonio R, Croteau SE, Dunn AL, Key NS, Iorio A. Outcomes for studies assessing the efficacy of hemostatic therapies in persons with congenital bleeding disorders. Haemophilia. 2021 Mar; 27: 211-220.
Kuhn AK, Saini S, Stanek J, Dunn A, Kumar R. Unfractionated heparin using actual body weight without dose capping in obese pediatric patients-Subgroup analysis from an observational cohort study. Pediatr Blood Cancer. 2021 Mar; 68: e28872.
Abdelghani E, Dawson J, Zajo K, Hallam M, Dunn A, Kumar R. Fibrinogen Columbus III: A novel c.963del frameshift mutation in the FGG gene resulting in hypofibrinogenemia with a bleeding phenotype. Pediatr Blood Cancer. 2021 Mar; 68: e28713.
Konkle BA, Quon DV, Raffini L, Recht M, Radulescu VC, Carpenter SL, Dunn AL, Lu M, Watt M. A Prospective Observational Study of Antihemophilic Factor (Recombinant) Prophylaxis Related to Physical Activity Levels in Patients with Hemophilia A in the United States (SPACE). J Blood Med. 2021; 12: 883-896.
Davis KA, Stanek JR, Dunn AL. Screening urinalysis demonstrates that haematuria is a frequent finding in persons with haemophilia treated at a paediatric haemophilia treatment centre. Haemophilia. 2019 Jul 10;
Saini S, Folta AN, Harsh KL, Stanek JR, Dunn AL, O'Brien SH, Kumar R. Anti-Factor Xa-Based Monitoring of Unfractionated Heparin: Clinical Outcomes in a Pediatric Cohort. J Pediatr. 2019 Jun; 209: 212-219.e1.
Drayton Jackson M, Bartman T, McGinniss J, Widener P, Dunn AL. Optimizing patient flow in a multidisciplinary haemophilia clinic using quality improvement methodology. Haemophilia. 2019 May 29;
Kumar R, Dawson J, Varga E, Canini JT, Monda KL, Dunn AL. Fibrinogen Columbus II: A novel c.1075G>T mutation in the FGG gene causing hypodysfibrinogenemia and thrombosis in an adolescent male. Pediatr Blood Cancer. 2019 May 27; e27832.
Sharma R, Woods GM, Creary S, O'Brien S, Stanek J, Hor K, Gallagher C, Dunn AL, Kumar R. Impact of erythrocytapheresis on natural anticoagulant levels in children with sickle cell disease: A pilot study. Pediatr Blood Cancer. 2019 Apr; 66: e27588.
Drayton Jackson M, Dunn MW, Storey MA, Dunn AL. Increasing optimal coagulation factor dosing in the paediatric emergency department: A quality improvement study. Haemophilia. 2019 Mar; 25: 258-263.
Saini S, Croteau SE, Horling FM, Dunn AL. Factor IX inhibitors: Clinical and laboratory profiles of two patients with severe haemophilia B. Haemophilia. 2019 Mar; 25: e126-e129.
Dunn A, Patterson J, Biega CF, Grishchenko A, Luna J, Stanek JR, Strouse R. A Novel Clinician-Orchestrated Virtual Reality Platform for Distraction During Pediatric Intravenous Procedures in Children With Hemophilia: Randomized Controlled Trial. JMIR Serious Games. 2019 Jan 9; 7: e10902.
Young G, Callaghan M, Dunn A, Kruse-Jarres R, Pipe S. Emicizumab for hemophilia A with factor VIII inhibitors. Expert Rev Hematol. 2018 Nov; 11: 835-846.
Bergin SM, Dunn AL, Smith LGF, Drapeau AI. Management of hydrocephalus in infants with severe hemophilia A: report of 2 cases. J Neurosurg Pediatr. 2018 Nov 2; 23: 159-163.
Drayton Jackson M, O'Brien SH, Stanek J, Dunn AL, Kerlin BA. Inpatient Health Care Utilization in Children With Hemophilia Before and After the Joint Outcome Study Publication. J Pediatr Hematol Oncol. 2018 Oct 18;
Croteau SE, Callaghan MU, Davis J, Dunn AL, Guerrera M, Khan O, Neufeld EJ, Raffini LJ, Recht M, Wang M, Iorio A. Focusing in on use of pharmacokinetic profiles in routine hemophilia care. Res Pract Thromb Haemost. 2018 Jul; 2: 607-614.
View More Publications
Publications
Pierce GF, Adediran M, Diop S, Dunn AL, El Ekiaby M, Kaczmarek R, Konkle BA, Pipe SW, Skinner MW, Valentino LA, Robinson F, Ampartzidis G, Martin J, Haffar A. Achieving access to haemophilia care in low-income and lower-middle-income countries: expanded Humanitarian Aid Program of the World Federation of Hemophilia after 5 years. Lancet Haematol. 2022 Sep; 9: e689-e697.
Kumar R, Dunn A, Schneiderman JE, Gonzales A, Bouskill V, Widener P, Stanek J, Pluthero FG, Waller A, Tarango C, Ahuja S, Kerlin BA, Kahr WH, Rand ML, Lillicrap D, Carcao M. Moderate-intensity aerobic exercise versus desmopressin in adolescent males with mild hemophilia A: a randomized trial. Blood. 2022 Jul 15;
Escobar M, Dunn A, Quon D, Trzaskoma B, Lee L, Ko RH, Carpenter SL. A phase IV, multicentre, open-label study of emicizumab prophylaxis in people with haemophilia A with or without FVIII inhibitors undergoing minor surgical procedures. Haemophilia. 2022 May 5;
Pipe SW, Hermans C, Chitlur M, Carcao M, Castaman G, Davis JA, Ducore J, Dunn AL, Escobar M, Journeycake J, Khan O, Mahlangu J, Meeks SL, Mitha IH, Négrier C, Nowak-Göttl U, Recht M, Chrisentery-Singleton T, Stasyshyn O, Vilchevska KV, Martinez LV, Wang M, Windyga J, Young G, Alexander WA, Bonzo D, Macie C, Mitchell IS, Sauty E, Wilkinson TA, Shapiro AD. Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors. Haemophilia. 2022 Apr 27;
Königs C, Ozelo MC, Dunn A, Kulkarni R, Nolan B, Brown SA, Schiavulli M, Gunawardena S, Mukhopadhyay S, Jayawardene D, Winding B, Carcao M. First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results. Blood. 2022 Apr 12;
Rodriguez V, Stanek J, Kerlin BA, Dunn AL. Andexanet Alfa Versus Prothrombin Complex Concentrates/Blood Products as Apixaban/Rivaroxaban Reversal Agents: A Survey Among Pediatric Hematologists. Clin Appl Thromb Hemost. 2022 Jan-Dec; 28: 10760296221078842.
Wysocki EL, Kuhn A, Steinbrenner J, Tyrrell L, Abdel-Rasoul M, Dunn A, Cloyd C. Enoxaparin Dose Requirements to Achieve Therapeutic Low-molecular-weight Heparin Anti-factor Xa Levels in Infants and Young Children. J Pediatr Hematol Oncol. 2021 Oct 1; 43: e946-e950.
Giver J, Dunn AL, Sankar A, Stanek J, Monda K, Canini J, Kerlin BA, Rodriguez V. Drive-through Anticoagulation Clinic During The COVID-19 Pandemic. J Nurse Pract. 2021 Sep 8;
Bakeer N, Dover S, Babyn P, Feldman BM, von Drygalski A, Doria AS, Ignas DM, Abad A, Bailey C, Beggs I, Chang EY, Dunn A, Funk S, Gibikote S, Goddard N, Hilliard P, Keshava SN, Kruse-Jarres R, Li Y, Lobet S, Manco-Johnson M, Martinoli C, O'Donnell JS, Papakonstantinou O, Pergantou H, Poonnoose P, Querol F, Srivastava A, Steiner B, Strike K, Timmer M, Tyrrell PN, Vidarsson L, Blanchette VS. Musculoskeletal ultrasound in hemophilia: Results and recommendations from a global survey and consensus meeting. Res Pract Thromb Haemost. 2021 Jul; 5: e12531.
Aquino CC, Borg Debono V, Germini F, Pete D, Kempton CL, Young G, Sidonio R, Croteau SE, Dunn AL, Key NS, Iorio A. Outcomes for studies assessing the efficacy of hemostatic therapies in persons with congenital bleeding disorders. Haemophilia. 2021 Mar; 27: 211-220.
Kuhn AK, Saini S, Stanek J, Dunn A, Kumar R. Unfractionated heparin using actual body weight without dose capping in obese pediatric patients-Subgroup analysis from an observational cohort study. Pediatr Blood Cancer. 2021 Mar; 68: e28872.
Abdelghani E, Dawson J, Zajo K, Hallam M, Dunn A, Kumar R. Fibrinogen Columbus III: A novel c.963del frameshift mutation in the FGG gene resulting in hypofibrinogenemia with a bleeding phenotype. Pediatr Blood Cancer. 2021 Mar; 68: e28713.
Konkle BA, Quon DV, Raffini L, Recht M, Radulescu VC, Carpenter SL, Dunn AL, Lu M, Watt M. A Prospective Observational Study of Antihemophilic Factor (Recombinant) Prophylaxis Related to Physical Activity Levels in Patients with Hemophilia A in the United States (SPACE). J Blood Med. 2021; 12: 883-896.
Davis KA, Stanek JR, Dunn AL. Screening urinalysis demonstrates that haematuria is a frequent finding in persons with haemophilia treated at a paediatric haemophilia treatment centre. Haemophilia. 2019 Jul 10;
Saini S, Folta AN, Harsh KL, Stanek JR, Dunn AL, O'Brien SH, Kumar R. Anti-Factor Xa-Based Monitoring of Unfractionated Heparin: Clinical Outcomes in a Pediatric Cohort. J Pediatr. 2019 Jun; 209: 212-219.e1.
Drayton Jackson M, Bartman T, McGinniss J, Widener P, Dunn AL. Optimizing patient flow in a multidisciplinary haemophilia clinic using quality improvement methodology. Haemophilia. 2019 May 29;
Kumar R, Dawson J, Varga E, Canini JT, Monda KL, Dunn AL. Fibrinogen Columbus II: A novel c.1075G>T mutation in the FGG gene causing hypodysfibrinogenemia and thrombosis in an adolescent male. Pediatr Blood Cancer. 2019 May 27; e27832.
Sharma R, Woods GM, Creary S, O'Brien S, Stanek J, Hor K, Gallagher C, Dunn AL, Kumar R. Impact of erythrocytapheresis on natural anticoagulant levels in children with sickle cell disease: A pilot study. Pediatr Blood Cancer. 2019 Apr; 66: e27588.
Drayton Jackson M, Dunn MW, Storey MA, Dunn AL. Increasing optimal coagulation factor dosing in the paediatric emergency department: A quality improvement study. Haemophilia. 2019 Mar; 25: 258-263.
Saini S, Croteau SE, Horling FM, Dunn AL. Factor IX inhibitors: Clinical and laboratory profiles of two patients with severe haemophilia B. Haemophilia. 2019 Mar; 25: e126-e129.
Dunn A, Patterson J, Biega CF, Grishchenko A, Luna J, Stanek JR, Strouse R. A Novel Clinician-Orchestrated Virtual Reality Platform for Distraction During Pediatric Intravenous Procedures in Children With Hemophilia: Randomized Controlled Trial. JMIR Serious Games. 2019 Jan 9; 7: e10902.
Young G, Callaghan M, Dunn A, Kruse-Jarres R, Pipe S. Emicizumab for hemophilia A with factor VIII inhibitors. Expert Rev Hematol. 2018 Nov; 11: 835-846.
Bergin SM, Dunn AL, Smith LGF, Drapeau AI. Management of hydrocephalus in infants with severe hemophilia A: report of 2 cases. J Neurosurg Pediatr. 2018 Nov 2; 23: 159-163.
Drayton Jackson M, O'Brien SH, Stanek J, Dunn AL, Kerlin BA. Inpatient Health Care Utilization in Children With Hemophilia Before and After the Joint Outcome Study Publication. J Pediatr Hematol Oncol. 2018 Oct 18;
Croteau SE, Callaghan MU, Davis J, Dunn AL, Guerrera M, Khan O, Neufeld EJ, Raffini LJ, Recht M, Wang M, Iorio A. Focusing in on use of pharmacokinetic profiles in routine hemophilia care. Res Pract Thromb Haemost. 2018 Jul; 2: 607-614.
View More Publications
Pierce GF, Adediran M, Diop S, Dunn AL, El Ekiaby M, Kaczmarek R, Konkle BA, Pipe SW, Skinner MW, Valentino LA, Robinson F, Ampartzidis G, Martin J, Haffar A. Achieving access to haemophilia care in low-income and lower-middle-income countries: expanded Humanitarian Aid Program of the World Federation of Hemophilia after 5 years. Lancet Haematol. 2022 Sep; 9: e689-e697.
Kumar R, Dunn A, Schneiderman JE, Gonzales A, Bouskill V, Widener P, Stanek J, Pluthero FG, Waller A, Tarango C, Ahuja S, Kerlin BA, Kahr WH, Rand ML, Lillicrap D, Carcao M. Moderate-intensity aerobic exercise versus desmopressin in adolescent males with mild hemophilia A: a randomized trial. Blood. 2022 Jul 15;
Escobar M, Dunn A, Quon D, Trzaskoma B, Lee L, Ko RH, Carpenter SL. A phase IV, multicentre, open-label study of emicizumab prophylaxis in people with haemophilia A with or without FVIII inhibitors undergoing minor surgical procedures. Haemophilia. 2022 May 5;
Pipe SW, Hermans C, Chitlur M, Carcao M, Castaman G, Davis JA, Ducore J, Dunn AL, Escobar M, Journeycake J, Khan O, Mahlangu J, Meeks SL, Mitha IH, Négrier C, Nowak-Göttl U, Recht M, Chrisentery-Singleton T, Stasyshyn O, Vilchevska KV, Martinez LV, Wang M, Windyga J, Young G, Alexander WA, Bonzo D, Macie C, Mitchell IS, Sauty E, Wilkinson TA, Shapiro AD. Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors. Haemophilia. 2022 Apr 27;
Königs C, Ozelo MC, Dunn A, Kulkarni R, Nolan B, Brown SA, Schiavulli M, Gunawardena S, Mukhopadhyay S, Jayawardene D, Winding B, Carcao M. First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results. Blood. 2022 Apr 12;
Rodriguez V, Stanek J, Kerlin BA, Dunn AL. Andexanet Alfa Versus Prothrombin Complex Concentrates/Blood Products as Apixaban/Rivaroxaban Reversal Agents: A Survey Among Pediatric Hematologists. Clin Appl Thromb Hemost. 2022 Jan-Dec; 28: 10760296221078842.
Wysocki EL, Kuhn A, Steinbrenner J, Tyrrell L, Abdel-Rasoul M, Dunn A, Cloyd C. Enoxaparin Dose Requirements to Achieve Therapeutic Low-molecular-weight Heparin Anti-factor Xa Levels in Infants and Young Children. J Pediatr Hematol Oncol. 2021 Oct 1; 43: e946-e950.
Giver J, Dunn AL, Sankar A, Stanek J, Monda K, Canini J, Kerlin BA, Rodriguez V. Drive-through Anticoagulation Clinic During The COVID-19 Pandemic. J Nurse Pract. 2021 Sep 8;
Bakeer N, Dover S, Babyn P, Feldman BM, von Drygalski A, Doria AS, Ignas DM, Abad A, Bailey C, Beggs I, Chang EY, Dunn A, Funk S, Gibikote S, Goddard N, Hilliard P, Keshava SN, Kruse-Jarres R, Li Y, Lobet S, Manco-Johnson M, Martinoli C, O'Donnell JS, Papakonstantinou O, Pergantou H, Poonnoose P, Querol F, Srivastava A, Steiner B, Strike K, Timmer M, Tyrrell PN, Vidarsson L, Blanchette VS. Musculoskeletal ultrasound in hemophilia: Results and recommendations from a global survey and consensus meeting. Res Pract Thromb Haemost. 2021 Jul; 5: e12531.
Aquino CC, Borg Debono V, Germini F, Pete D, Kempton CL, Young G, Sidonio R, Croteau SE, Dunn AL, Key NS, Iorio A. Outcomes for studies assessing the efficacy of hemostatic therapies in persons with congenital bleeding disorders. Haemophilia. 2021 Mar; 27: 211-220.
Kuhn AK, Saini S, Stanek J, Dunn A, Kumar R. Unfractionated heparin using actual body weight without dose capping in obese pediatric patients-Subgroup analysis from an observational cohort study. Pediatr Blood Cancer. 2021 Mar; 68: e28872.
Abdelghani E, Dawson J, Zajo K, Hallam M, Dunn A, Kumar R. Fibrinogen Columbus III: A novel c.963del frameshift mutation in the FGG gene resulting in hypofibrinogenemia with a bleeding phenotype. Pediatr Blood Cancer. 2021 Mar; 68: e28713.
Konkle BA, Quon DV, Raffini L, Recht M, Radulescu VC, Carpenter SL, Dunn AL, Lu M, Watt M. A Prospective Observational Study of Antihemophilic Factor (Recombinant) Prophylaxis Related to Physical Activity Levels in Patients with Hemophilia A in the United States (SPACE). J Blood Med. 2021; 12: 883-896.
Davis KA, Stanek JR, Dunn AL. Screening urinalysis demonstrates that haematuria is a frequent finding in persons with haemophilia treated at a paediatric haemophilia treatment centre. Haemophilia. 2019 Jul 10;
Saini S, Folta AN, Harsh KL, Stanek JR, Dunn AL, O'Brien SH, Kumar R. Anti-Factor Xa-Based Monitoring of Unfractionated Heparin: Clinical Outcomes in a Pediatric Cohort. J Pediatr. 2019 Jun; 209: 212-219.e1.
Drayton Jackson M, Bartman T, McGinniss J, Widener P, Dunn AL. Optimizing patient flow in a multidisciplinary haemophilia clinic using quality improvement methodology. Haemophilia. 2019 May 29;
Kumar R, Dawson J, Varga E, Canini JT, Monda KL, Dunn AL. Fibrinogen Columbus II: A novel c.1075G>T mutation in the FGG gene causing hypodysfibrinogenemia and thrombosis in an adolescent male. Pediatr Blood Cancer. 2019 May 27; e27832.
Sharma R, Woods GM, Creary S, O'Brien S, Stanek J, Hor K, Gallagher C, Dunn AL, Kumar R. Impact of erythrocytapheresis on natural anticoagulant levels in children with sickle cell disease: A pilot study. Pediatr Blood Cancer. 2019 Apr; 66: e27588.
Drayton Jackson M, Dunn MW, Storey MA, Dunn AL. Increasing optimal coagulation factor dosing in the paediatric emergency department: A quality improvement study. Haemophilia. 2019 Mar; 25: 258-263.
Saini S, Croteau SE, Horling FM, Dunn AL. Factor IX inhibitors: Clinical and laboratory profiles of two patients with severe haemophilia B. Haemophilia. 2019 Mar; 25: e126-e129.
Dunn A, Patterson J, Biega CF, Grishchenko A, Luna J, Stanek JR, Strouse R. A Novel Clinician-Orchestrated Virtual Reality Platform for Distraction During Pediatric Intravenous Procedures in Children With Hemophilia: Randomized Controlled Trial. JMIR Serious Games. 2019 Jan 9; 7: e10902.
Young G, Callaghan M, Dunn A, Kruse-Jarres R, Pipe S. Emicizumab for hemophilia A with factor VIII inhibitors. Expert Rev Hematol. 2018 Nov; 11: 835-846.
Bergin SM, Dunn AL, Smith LGF, Drapeau AI. Management of hydrocephalus in infants with severe hemophilia A: report of 2 cases. J Neurosurg Pediatr. 2018 Nov 2; 23: 159-163.
Drayton Jackson M, O'Brien SH, Stanek J, Dunn AL, Kerlin BA. Inpatient Health Care Utilization in Children With Hemophilia Before and After the Joint Outcome Study Publication. J Pediatr Hematol Oncol. 2018 Oct 18;
Croteau SE, Callaghan MU, Davis J, Dunn AL, Guerrera M, Khan O, Neufeld EJ, Raffini LJ, Recht M, Wang M, Iorio A. Focusing in on use of pharmacokinetic profiles in routine hemophilia care. Res Pract Thromb Haemost. 2018 Jul; 2: 607-614.
View More Publications
- Pierce GF, Adediran M, Diop S, Dunn AL, El Ekiaby M, Kaczmarek R, Konkle BA, Pipe SW, Skinner MW, Valentino LA, Robinson F, Ampartzidis G, Martin J, Haffar A. Achieving access to haemophilia care in low-income and lower-middle-income countries: expanded Humanitarian Aid Program of the World Federation of Hemophilia after 5 years. Lancet Haematol. 2022 Sep; 9: e689-e697.
- Kumar R, Dunn A, Schneiderman JE, Gonzales A, Bouskill V, Widener P, Stanek J, Pluthero FG, Waller A, Tarango C, Ahuja S, Kerlin BA, Kahr WH, Rand ML, Lillicrap D, Carcao M. Moderate-intensity aerobic exercise versus desmopressin in adolescent males with mild hemophilia A: a randomized trial. Blood. 2022 Jul 15;
- Escobar M, Dunn A, Quon D, Trzaskoma B, Lee L, Ko RH, Carpenter SL. A phase IV, multicentre, open-label study of emicizumab prophylaxis in people with haemophilia A with or without FVIII inhibitors undergoing minor surgical procedures. Haemophilia. 2022 May 5;
- Pipe SW, Hermans C, Chitlur M, Carcao M, Castaman G, Davis JA, Ducore J, Dunn AL, Escobar M, Journeycake J, Khan O, Mahlangu J, Meeks SL, Mitha IH, Négrier C, Nowak-Göttl U, Recht M, Chrisentery-Singleton T, Stasyshyn O, Vilchevska KV, Martinez LV, Wang M, Windyga J, Young G, Alexander WA, Bonzo D, Macie C, Mitchell IS, Sauty E, Wilkinson TA, Shapiro AD. Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors. Haemophilia. 2022 Apr 27;
- Königs C, Ozelo MC, Dunn A, Kulkarni R, Nolan B, Brown SA, Schiavulli M, Gunawardena S, Mukhopadhyay S, Jayawardene D, Winding B, Carcao M. First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results. Blood. 2022 Apr 12;
- Rodriguez V, Stanek J, Kerlin BA, Dunn AL. Andexanet Alfa Versus Prothrombin Complex Concentrates/Blood Products as Apixaban/Rivaroxaban Reversal Agents: A Survey Among Pediatric Hematologists. Clin Appl Thromb Hemost. 2022 Jan-Dec; 28: 10760296221078842.
- Wysocki EL, Kuhn A, Steinbrenner J, Tyrrell L, Abdel-Rasoul M, Dunn A, Cloyd C. Enoxaparin Dose Requirements to Achieve Therapeutic Low-molecular-weight Heparin Anti-factor Xa Levels in Infants and Young Children. J Pediatr Hematol Oncol. 2021 Oct 1; 43: e946-e950.
- Giver J, Dunn AL, Sankar A, Stanek J, Monda K, Canini J, Kerlin BA, Rodriguez V. Drive-through Anticoagulation Clinic During The COVID-19 Pandemic. J Nurse Pract. 2021 Sep 8;
- Bakeer N, Dover S, Babyn P, Feldman BM, von Drygalski A, Doria AS, Ignas DM, Abad A, Bailey C, Beggs I, Chang EY, Dunn A, Funk S, Gibikote S, Goddard N, Hilliard P, Keshava SN, Kruse-Jarres R, Li Y, Lobet S, Manco-Johnson M, Martinoli C, O’Donnell JS, Papakonstantinou O, Pergantou H, Poonnoose P, Querol F, Srivastava A, Steiner B, Strike K, Timmer M, Tyrrell PN, Vidarsson L, Blanchette VS. Musculoskeletal ultrasound in hemophilia: Results and recommendations from a global survey and consensus meeting. Res Pract Thromb Haemost. 2021 Jul; 5: e12531.
- Aquino CC, Borg Debono V, Germini F, Pete D, Kempton CL, Young G, Sidonio R, Croteau SE, Dunn AL, Key NS, Iorio A. Outcomes for studies assessing the efficacy of hemostatic therapies in persons with congenital bleeding disorders. Haemophilia. 2021 Mar; 27: 211-220.
- Kuhn AK, Saini S, Stanek J, Dunn A, Kumar R. Unfractionated heparin using actual body weight without dose capping in obese pediatric patients-Subgroup analysis from an observational cohort study. Pediatr Blood Cancer. 2021 Mar; 68: e28872.
- Abdelghani E, Dawson J, Zajo K, Hallam M, Dunn A, Kumar R. Fibrinogen Columbus III: A novel c.963del frameshift mutation in the FGG gene resulting in hypofibrinogenemia with a bleeding phenotype. Pediatr Blood Cancer. 2021 Mar; 68: e28713.
- Konkle BA, Quon DV, Raffini L, Recht M, Radulescu VC, Carpenter SL, Dunn AL, Lu M, Watt M. A Prospective Observational Study of Antihemophilic Factor (Recombinant) Prophylaxis Related to Physical Activity Levels in Patients with Hemophilia A in the United States (SPACE). J Blood Med. 2021; 12: 883-896.
- Davis KA, Stanek JR, Dunn AL. Screening urinalysis demonstrates that haematuria is a frequent finding in persons with haemophilia treated at a paediatric haemophilia treatment centre. Haemophilia. 2019 Jul 10;
- Saini S, Folta AN, Harsh KL, Stanek JR, Dunn AL, O’Brien SH, Kumar R. Anti-Factor Xa-Based Monitoring of Unfractionated Heparin: Clinical Outcomes in a Pediatric Cohort. J Pediatr. 2019 Jun; 209: 212-219.e1.
- Drayton Jackson M, Bartman T, McGinniss J, Widener P, Dunn AL. Optimizing patient flow in a multidisciplinary haemophilia clinic using quality improvement methodology. Haemophilia. 2019 May 29;
- Kumar R, Dawson J, Varga E, Canini JT, Monda KL, Dunn AL. Fibrinogen Columbus II: A novel c.1075G>T mutation in the FGG gene causing hypodysfibrinogenemia and thrombosis in an adolescent male. Pediatr Blood Cancer. 2019 May 27; e27832.
- Sharma R, Woods GM, Creary S, O’Brien S, Stanek J, Hor K, Gallagher C, Dunn AL, Kumar R. Impact of erythrocytapheresis on natural anticoagulant levels in children with sickle cell disease: A pilot study. Pediatr Blood Cancer. 2019 Apr; 66: e27588.
- Drayton Jackson M, Dunn MW, Storey MA, Dunn AL. Increasing optimal coagulation factor dosing in the paediatric emergency department: A quality improvement study. Haemophilia. 2019 Mar; 25: 258-263.
- Saini S, Croteau SE, Horling FM, Dunn AL. Factor IX inhibitors: Clinical and laboratory profiles of two patients with severe haemophilia B. Haemophilia. 2019 Mar; 25: e126-e129.
- Dunn A, Patterson J, Biega CF, Grishchenko A, Luna J, Stanek JR, Strouse R. A Novel Clinician-Orchestrated Virtual Reality Platform for Distraction During Pediatric Intravenous Procedures in Children With Hemophilia: Randomized Controlled Trial. JMIR Serious Games. 2019 Jan 9; 7: e10902.
- Young G, Callaghan M, Dunn A, Kruse-Jarres R, Pipe S. Emicizumab for hemophilia A with factor VIII inhibitors. Expert Rev Hematol. 2018 Nov; 11: 835-846.
- Bergin SM, Dunn AL, Smith LGF, Drapeau AI. Management of hydrocephalus in infants with severe hemophilia A: report of 2 cases. J Neurosurg Pediatr. 2018 Nov 2; 23: 159-163.
- Drayton Jackson M, O’Brien SH, Stanek J, Dunn AL, Kerlin BA. Inpatient Health Care Utilization in Children With Hemophilia Before and After the Joint Outcome Study Publication. J Pediatr Hematol Oncol. 2018 Oct 18;
- Croteau SE, Callaghan MU, Davis J, Dunn AL, Guerrera M, Khan O, Neufeld EJ, Raffini LJ, Recht M, Wang M, Iorio A. Focusing in on use of pharmacokinetic profiles in routine hemophilia care. Res Pract Thromb Haemost. 2018 Jul; 2: 607-614.
Education
Date of Appointment at Nationwide Children’s Hospital: 01/24/2014
Board Certifications
Pediatric Hematology Oncology Pediatrics
Fellowship
Emory University/Children’s Healthcare of Atlanta
Date Completed: 06/30/2000
Residency
Emory University/Children’s Healthcare of Atlanta
Date Completed: 06/30/1997
Medical School
Wright State University School of Medicine
Date Completed: 05/31/1994
Education
Date of Appointment at Nationwide Children’s Hospital: 01/24/2014
Board Certifications
Pediatric Hematology Oncology Pediatrics
Fellowship
Emory University/Children’s Healthcare of Atlanta
Date Completed: 06/30/2000
Residency
Emory University/Children’s Healthcare of Atlanta
Date Completed: 06/30/1997
Medical School
Wright State University School of Medicine
Date Completed: 05/31/1994
Education
Date of Appointment at Nationwide Children’s Hospital: 01/24/2014
Board Certifications
Pediatric Hematology Oncology Pediatrics
Fellowship
Emory University/Children’s Healthcare of Atlanta
Date Completed: 06/30/2000
Residency
Emory University/Children’s Healthcare of Atlanta
Date Completed: 06/30/1997
Medical School
Wright State University School of Medicine
Date Completed: 05/31/1994
Date of Appointment at Nationwide Children’s Hospital: 01/24/2014
Board Certifications
Pediatric Hematology Oncology Pediatrics
Fellowship
Emory University/Children’s Healthcare of Atlanta
Date Completed: 06/30/2000
Residency
Emory University/Children’s Healthcare of Atlanta
Date Completed: 06/30/1997
Medical School
Wright State University School of Medicine
Date Completed: 05/31/1994
Date of Appointment at Nationwide Children’s Hospital: 01/24/2014
Board Certifications
Pediatric Hematology Oncology Pediatrics
Fellowship
Emory University/Children’s Healthcare of Atlanta
Date Completed: 06/30/2000
Residency
Emory University/Children’s Healthcare of Atlanta
Date Completed: 06/30/1997
Medical School
Wright State University School of Medicine
Date Completed: 05/31/1994
- Pediatric Hematology Oncology
- Pediatrics
Contact Information
Pediatrics
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)
Contact Information
Pediatrics
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)
Contact Information
Pediatrics
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)
Pediatrics
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)
- Call us at:
- (614) 722-3550
- Fax us at:
- (614) 722-3369
- Hematology & Oncology700 Children’s DrColumbus, OH 43205 (map)
